Can local prostatic inflammation contribute to benign prostatic hyperplasia?

Local prostatic inflammation is biologically credible as a contributor to BPH-related enlargement and impaired voiding, but the clinical evidence supports association more firmly than a proven causal role in BPH onset or overall progression.

Clinical evidence

• Histologic prostatitis accompanying BPH is associated with larger prostate volume: a 2025 systematic review/meta-analysis found approximately 13.8 mL greater volume in cross-sectional data and 10.2 mL greater volume in cohort data.
• Inflammation is also associated with clinically important adverse outcomes. In the REDUCE biopsy substudy, chronic inflammation predicted acute urinary retention (HR 1.79, 95% CI 1.31–2.44). MTOPS similarly observed retention in 5.6% of men with baseline inflammation and none without it.
• Pooled cohort data found a 2.42 mL/s lower Qmax in men with histologic prostatitis. This is compatible with poorer outflow, but Qmax alone cannot establish bladder outlet obstruction; detrusor underactivity and voiding conditions also affect flow.

Mechanistic basis

• Inflammatory signaling can promote both compartments of BPH tissue in experimental systems. IL-8 can directly stimulate BPH stromal-cell proliferation and induce stromal FGF-2 through epithelial–stromal signaling.
• Mast-cell-derived IL-6 promotes epithelial proliferation, STAT3 phosphorylation, and Cyclin D1 expression; IL-6/IL-6-receptor, JAK1/2, or STAT3 inhibition attenuates these effects.
• Chronic inflammatory signaling may also promote fibromuscular remodeling: TGF-β/Smad activation supports myofibroblast differentiation, collagen/extracellular-matrix deposition, fibrosis, and tissue stiffness. TNF-α–TGF-β1/Smad2/3 signaling has produced similar proliferative and fibrotic effects in prostate-cell models.

Clinical interpretation

• Inflammation-associated enlargement or remodeling may worsen outlet resistance in some men, but direct evidence of edema causing independently measured obstruction is limited. Evaluation should distinguish obstruction from impaired bladder contractility when relevant.

Bottom line

• Local inflammation is a plausible contributor to BPH burden, enlargement, and retention risk through cytokine-driven growth and remodeling, but it should not be regarded as an established primary cause of BPH or obstruction.